Arcutis Biotherapeutics Inc (ARQT)

05:53 AM

What analysts say about Arcutis Biotherapeutics Inc. stockExplosive portfolio gains - Jammu Links News

05:53 AM

05:26 AM

Arcutis Biotherapeutics Inc. Stock Analysis and ForecastSky-high return potential - Jammu Links News

05:26 AM

03:24 AM

What drives Arcutis Biotherapeutics Inc. stock priceExplosive capital gains - Autocar Professional

03:24 AM

Jul 18, 2025

Is Arcutis Biotherapeutics Inc. a good long term investmentTriple-digit wealth increases - Jammu Links News

Jul 18, 2025

Jul 17, 2025

Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study - TipRanks

Jul 17, 2025

Jul 15, 2025

Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load? - simplywall.st

Jul 15, 2025

Jul 14, 2025

Arcutis Bio EVP Burnett sells $432k in ARQT stock after option exercise - Investing.com Canada

Jul 14, 2025

Jul 14, 2025

Arcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis - MSN

Jul 14, 2025

Jul 11, 2025

FDA News and Decisions: Midyear Updates - Dermatology Times

Jul 11, 2025

Jul 10, 2025

Arcutis Biotherapeutics Stock Scores RS Rating Upgrade - MSN

Jul 10, 2025

Jul 09, 2025

(ARQT) Investment Analysis - news.stocktradersdaily.com

Jul 09, 2025

Jul 09, 2025

Arcutis Biotherapeutics - WBFF

Jul 09, 2025

Jul 09, 2025

Uncovering Plaque Psoriasis: Exploring New FDA-Approved Topical Treatment - ABC Action News

Jul 09, 2025

Jul 04, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 04, 2025

Jul 03, 2025

Morgan Stanley assumes coverage of Arcutis Biotherapeutics stock with Overweight rating - Investing.com Nigeria

Jul 03, 2025

Jul 03, 2025

Arcutis Awards Generous Stock Compensation Package: 14,000 RSUs for Two New Hires - Stock Titan

Jul 03, 2025

Jun 27, 2025

Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis - Contemporary Pediatrics

Jun 27, 2025

Jun 26, 2025

Arcutis Biotherapeutics (ARQT) Gains Strong AAD Recommendation for ZORYVE Cream | ARQT Stock News - GuruFocus

Jun 26, 2025

Jun 26, 2025

Arcutis Biotherapeutics' Zoryve Cream Receives Recommendation From American Academy of Dermatology - MarketScreener

Jun 26, 2025

Jun 25, 2025

Arcutis Biotherapeutics: Another Approval Under Their Belt - Seeking Alpha

Jun 25, 2025

Jun 23, 2025

Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st

Jun 23, 2025

Jun 18, 2025

When (ARQT) Moves Investors should Listen - news.stocktradersdaily.com

Jun 18, 2025

Jun 18, 2025

Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long - Yahoo Finance

Jun 18, 2025

Jun 17, 2025

Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials - MSN

Jun 17, 2025

Jun 17, 2025

Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks

Jun 17, 2025

Jun 12, 2025

Arcutis: Out Of The Woods, Ready For Commercialization - Seeking Alpha

Jun 12, 2025

Jun 11, 2025

10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey

Jun 11, 2025

Jun 11, 2025

First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis - Yahoo Finance

Jun 11, 2025

Jun 10, 2025

Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com South Africa

Jun 10, 2025

Jun 10, 2025

Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Australia

Jun 10, 2025

Jun 10, 2025

Arcutis Biotherapeutics (ARQT) Begins Trial for Infant Atopic De - GuruFocus

Jun 10, 2025

Jun 10, 2025

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis - Taiwan News

Jun 10, 2025

Jun 09, 2025

Arcutis says Zoryve data demonstrates durable atopic dermatitis improvements - MSN

Jun 09, 2025

Jun 09, 2025

H.C. Wainwright maintains $19 target on Arcutis stock - Investing.com Australia

Jun 09, 2025

Jun 09, 2025

H.C. Wainwright maintains $19 target on Arcutis stock By Investing.com - Investing.com South Africa

Jun 09, 2025

Jun 08, 2025

Wellington Management Group LLP Sells 3,882 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World

Jun 08, 2025

Jun 07, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq L - GuruFocus

Jun 07, 2025

Jun 06, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ARQT Stock News - GuruFocus

Jun 06, 2025

Jun 06, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com

Jun 06, 2025

Jun 06, 2025

Arcutis Grants 72,000 Restricted Stock Units to 9 New Hires: Key Details on 4-Year Vesting Plan - Stock Titan

Jun 06, 2025

Jun 06, 2025

Arcutis Presents Long-Term INTEGUMENT-OLE Data on Roflumilast at RAD 2025 - Dermatology Times

Jun 06, 2025

Jun 06, 2025

Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis - Benzinga

Jun 06, 2025

Jun 06, 2025

Road to RAD: What to Expect - Dermatology Times

Jun 06, 2025